Synthetic anticholinergics, quaternary ammonium compounds (ATC A03AB)

Synthetic anticholinergics of the quaternary ammonium type (ATC A03AB) are peripherally acting muscarinic antagonists used mainly for the symptomatic treatment of functional gastrointestinal disorders with smooth‑muscle spasm, such as irritable bowel syndrome and colicky abdominal pain. Their quaternary ammonium structure limits penetration across the blood–brain barrier, which reduces central nervous system effects compared with tertiary anticholinergics but does not eliminate systemic toxicity.medpedia.framar+2

This ATC group includes benzilone, glycopyrronium bromide, oxyphenonium, penthienate, propantheline, otilonium bromide, methantheline, tridihexethyl, isopropamide, hexocyclium, poldine, mepenzolate, bevonium, pipenzolate, diphemanil, several iodide/bromide salts (e.g. tiemonium iodide, prifinium bromide, timepidium bromide), fenpiverinium and oxyphenonium combinations.atcddd.fhi+1

Mechanism of action and pharmacokinetics

A03AB agents competitively inhibit muscarinic acetylcholine receptors in the gastrointestinal tract, leading to relaxation of intestinal smooth muscle, decreased motility and reduced visceral hypersensitivity. Their quaternary ammonium nature confers poor oral bioavailability and limited tissue penetration, but repeated dosing can still produce meaningful systemic antimuscarinic effects, particularly in vulnerable patients.drugbank+2

Most A03AB medicines act locally in the gut after oral administration, with minimal central penetration, but they may be formulated for oral, parenteral or rectal use depending on the specific compound (for example, glycopyrronium bromide has defined oral, parenteral and inhaled DDDs).* Renal excretion is often significant, and accumulation can occur in renal impairment, increasing toxic risk.sideeffects.embl+2

Toxicology profile

Acute and dose‑related toxicity

The toxic effects of A03AB drugs reflect exaggerated peripheral antimuscarinic activity: dry mouth, tachycardia, urinary retention, decreased sweating, mydriasis, blurred vision and intestinal hypomotility up to paralytic ileus. At higher exposures, there is a risk of cardiac rhythm disturbances, hyperthermia due to impaired thermoregulation, and severe constipation or urinary retention, especially in older patients or those with pre‑existing obstruction.english.prescrire+1

Although CNS effects are less prominent than with tertiary anticholinergics, confusion, agitation or somnolence may still appear in susceptible individuals, particularly the elderly, in cases of overdose or when several anticholinergic medicines are combined. Quaternary ammonium compounds can also precipitate angle‑closure glaucoma and worsen gastro‑oesophageal reflux due to reduced lower oesophageal sphincter tone.drugbank+1

Chronic and special‑population risks

Long‑term use of antispasmodics in pregnancy is discouraged because available data suggest possible maternal and fetal adverse effects (neuropsychiatric, cardiac and gastrointestinal) when antispasmodics are taken in the second and third trimesters, and long‑term outcomes are insufficiently studied. For several A03AB representatives (including otilonium and tiemonium), animal data are limited and human gestational safety data beyond the first trimester are lacking, so unnecessary exposure of the fetus should be avoided.english.prescrire

In neonates and infants, inadvertent exposure (e.g. through maternal medication close to delivery) may result in antimuscarinic toxicity with neurological and cardiac manifestations, and therefore use near term should be carefully reconsidered. Premature and medically fragile infants are at particularly increased risk from even modest anticholinergic loads.mayoclinic+1

Use during pregnancy

A03AB medicines are generally not first‑line in pregnancy, and benefit–risk evaluation must be individualized. For some antispasmodics, cohort data in the first trimester (e.g. for phloroglucinol, which is outside A03AB but in the same therapeutic family) did not show an increased malformation rate; however, extrapolation to quaternary anticholinergics is uncertain and should be made cautiously.ema.europa+1

Given the paucity of high‑quality human data for many A03AB compounds during the second and third trimesters, expert sources recommend avoiding elective use, particularly for mild, non‑threatening functional symptoms. When a woman has been inadvertently exposed early in pregnancy, counselling should address the limited evidence base and may include targeted ultrasound monitoring, especially if exposure involved high doses or combination therapy.ema.europa+1

Use during lactation

General principles

Almost any systemically administered medicine reaches breast milk in small amounts; risk depends on the drug’s physicochemical properties, dose, and infant characteristics. Quaternary ammonium anticholinergics are highly ionized and poorly lipid‑soluble, characteristics that tend to limit transfer into milk and oral absorption by the infant; nonetheless, specific lactation data are scarce for most A03AB substances.pharmaceutical-journal+2

Because most A03AB medicines are not licensed specifically for use in breastfeeding women, and infant safety data are limited, standard lactation references advise careful case‑by‑case assessment, considering alternative therapies with better‑established safety where possible.ncbi.nlm.nih+2

Glycopyrronium bromide

Glycopyrronium (glycopyrrolate, A03AB02) is one of the best characterized agents in this group. Contemporary anaesthesia guidelines explicitly state that glycopyrronium is compatible with breastfeeding, indicating that routine peri‑operative use does not require interruption of lactation. Its poor oral bioavailability and quaternary structure further limit infant exposure and systemic absorption from milk.droracle+3

Even so, repeated high‑dose use for chronic gastrointestinal indications should prompt monitoring of the breastfed infant for anticholinergic signs such as poor feeding, unusual somnolence, reduced bowel movements or difficulty urinating, and prompt medical evaluation if these occur.ncbi.nlm.nih+1

Other A03AB agents

For other A03AB medicines (e.g. oxyphenonium, propantheline, otilonium bromide, tiemonium iodide, fenpiverinium), published lactation data are minimal or absent in standard databases, and these drugs are typically not listed among routine “safe” medicines in breastfeeding guidance. In such cases, short‑term, low‑dose use might be acceptable when no safer alternative is suitable, but it should follow specialist consultation, and prolonged courses should generally be avoided in breastfeeding mothers when an alternative treatment with established lactation safety exists.pharmaceutical-journal+4

If exposure occurs, mothers should be advised to observe the infant for changes in feeding, sleep, behavior, bowel or urinary function, as with other medicines where data are limited. Premature or medically compromised infants warrant a more conservative approach, potentially including temporary avoidance or substitution of the maternal drug.mayoclinic+2

Clinical toxico‑lactological recommendations

• Use A03AB agents for clear indications of significant gastrointestinal spasm when benefits outweigh the potential anticholinergic risks, especially in pregnant or breastfeeding patients.medpedia.framar+2
• Prefer compounds with some supportive lactation data (e.g. glycopyrronium) over those with no information, and keep doses and duration as low and short as clinically feasible.atcddd.fhi+2
• Avoid elective antispasmodic therapy from this class in the second and third trimesters of pregnancy and near delivery; seek non‑pharmacological or better‑studied alternatives where possible.english.prescrire+1
• In breastfeeding, before prescribing, consult dedicated lactation resources (e.g. LactMed) and national or professional guidance, and document the shared decision with the patient.pharmaceutical-journal+2
• Monitor infants exposed via breast milk for anticholinergic effects (feeding difficulties, constipation, urinary retention, excessive sedation or irritability, visual symptoms), and discontinue or change maternal therapy if concerning signs appear.ncbi.nlm.nih+1